Press Releases Year None20212020201920182017 April 12, 2021 Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma PDF Version April 1, 2021 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version March 22, 2021 SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer PDF Version February 25, 2021 SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights PDF Version February 25, 2021 SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update PDF Version February 22, 2021 SpringWorks Therapeutics to Present at Upcoming Investor Conferences PDF Version February 4, 2021 SpringWorks Therapeutics to Present at the Guggenheim Healthcare Talks 2021 Oncology Day PDF Version January 5, 2021 SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference PDF Version December 15, 2020 SpringWorks Therapeutics Announces Executive Leadership Promotions PDF Version November 24, 2020 SpringWorks Therapeutics to Participate in the Evercore ISI HealthCONx Conference PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last »
April 12, 2021 Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
April 1, 2021 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
March 22, 2021 SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer PDF Version
February 25, 2021 SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights PDF Version
February 25, 2021 SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update PDF Version
February 4, 2021 SpringWorks Therapeutics to Present at the Guggenheim Healthcare Talks 2021 Oncology Day PDF Version
January 5, 2021 SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference PDF Version
November 24, 2020 SpringWorks Therapeutics to Participate in the Evercore ISI HealthCONx Conference PDF Version
